Spectrum/Onxeo Move Beleodaq Into Phase III As First-Line PTCL Therapy
This article was originally published in Scrip
Executive Summary
Spectrum Pharmaceuticals and Onxeo S.A. are moving their jointly developed histone deacetylase (HDAC) inhibitor, Beleodaq (belinostat), into Phase III trials on the back of positive Phase I results for the drug as a first-line treatment for peripheral T-cell lymphoma.